Parkinson’s UK & King’s College London Plan Pioneering Clinical Trial to Treat Psychosis in Parkinson’s Patients Using Cannabidiol

Parkinson’s UK & King’s College London Plan Pioneering Clinical Trial to Treat Psychosis in Parkinson’s Patients Using Cannabidiol

Parkinson’s UK, the largest charitable funder of Parkinson’s research in Europe, has partnered with investigators at King’s College London to invest £1.2 million in a pioneering Phase II clinical trial investigating the use of cannabidiol (CBD)—a compound found...
Kings College London: A Novel Gene Therapy Addressing Recessive Dystrophic Epidermolysis Bullosa (RDEB) Shows Promise

Kings College London: A Novel Gene Therapy Addressing Recessive Dystrophic Epidermolysis Bullosa (RDEB) Shows Promise

King’s College London, in collaboration with University College, London conducted a Phase I clinical trials focused on recessive dystrophic epidermolysis bullosa (RDEB), a severe form of blistering skin disease caused by mutations in COL7A1 gene. The UK-based study...

Pin It on Pinterest